Inventor · disambiguated record
Satoshi Obika
Also filed as: OBIKA SATOSHI
32 granted patents·19 pending applications·3,696 citations·filing 1998–2025
97Inventor score
Files withUNIV OSAKA17UNIV NAT CORP TOKYO MEDICAL & DENTAL8IMANISHI TAKESHI4MITSUBISHI TANABE PHARMA CORP4TAKESHI IMANISHI4
Top patents by PatentIndex Score
51 records- 0198US6770748B2Bicyclonucleoside and oligonucleotide analogueIMANISHI TAKESHI·Filed 2001·Granted Aug 3, 2004·1k cites·5 claims
- 0297US7427672B2Artificial nucleic acids of n-o bond crosslinkage typeIMANISHI TAKESHI·Filed 2004·Granted Sep 23, 2008·868 cites·20 claims
- 0397US6268490B1Bicyclonucleoside and oligonucleotide analoguesTAKESHI IMANISHI·Filed 1998·Granted Jul 31, 2001·1.3k cites·8 claims
- 0495US7217805B2Bicyclonucleoside analoguesSANKYO CO·Filed 2002·Granted May 15, 2007·85 cites·16 claims
- 0595US7053199B2Nucleoside analogs and oligonucleotide derivatives containing these analogsIMANISHI TAKESHI·Filed 2001·Granted May 30, 2006·139 cites·10 claims
- 0692USRE44779EBicyclonucleoside and oligonucleotide analoguesIMANISHI TAKESHI·Filed 1998·Granted Feb 25, 2014·178 cites·32 claims
- 0790US10337006B2Chimeric double-stranded nucleic acidUNIV NAT CORP TOKYO MEDICAL & DENTAL·Filed 2017·Granted Jul 2, 2019·7 cites·11 claims
- 0890US9611479B2Crosslinked nucleoside and nucleotideUNIV OSAKA·Filed 2015·Granted Apr 4, 2017·7 cites·11 claims
- 0990US7994145B2Bicyclonucleoside analoguesTAKESHI IMANISHI·Filed 2007·Granted Aug 9, 2011·17 cites·16 claims
- 1088US11034955B2Chimeric double-stranded nucleic acidUNIV NAT CORP TOKYO MEDICAL & DENTAL·Filed 2019·Granted Jun 15, 2021·2 cites·14 claims
- 1187US2024158790A1Chimeric double-stranded nucleic acidUNIV NAT CORP TOKYO MEDICAL & DENTAL·Filed 2023·Application pending·0 cites
- 1285US10329567B2Chimeric double-stranded nucleic acidUNIV NAT CORP TOKYO MEDICAL & DENTAL·Filed 2018·Granted Jun 25, 2019·3 cites·8 claims
- 1385US8541562B2Bridged artificial nucleoside and nucleotideOBIKA SATOSHI·Filed 2010·Granted Sep 24, 2013·30 cites·19 claims
- 1483US7615619B2Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereofTAKESHI IMANISHI·Filed 2003·Granted Nov 10, 2009·21 cites·34 claims
- 1577US12344841B2Chimeric double-stranded nucleic acidUNIV NAT CORP TOKYO MEDICAL & DENTAL·Filed 2021·Granted Jul 1, 2025·0 cites·37 claims
- 1677US10377789B2Oligonucleotide and artificial nucleoside having guanidine bridgeUNIV OSAKA·Filed 2013·Granted Aug 13, 2019·6 cites·7 claims
- 1776US11273222B2Antisense nucleic acid targeting PCSK9NAT CEREBRAL & CARDIOVASCULAR CT·Filed 2018·Granted Mar 15, 2022·2 cites·12 claims
- 1874US11286275B2Nucleic acid compound and oligonucleotideUNIV OSAKA·Filed 2018·Granted Mar 29, 2022·1 cites·15 claims
- 1974US11261440B2Antisense oligonucleic acidUNIV OSAKA·Filed 2018·Granted Mar 1, 2022·1 cites·13 claims
- 2073US9816089B2Chimeric double-stranded nucleic acidUNIV NAT CORP TOKYO MEDICAL & DENTAL·Filed 2014·Granted Nov 14, 2017·1 cites·11 claims
- 2169US9127280B2Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredientOBIKA SATOSHI·Filed 2011·Granted Sep 8, 2015·3 cites·10 claims
- 2269US2025340584A1Crosslinked artificial nucleic acid alnaMITSUBISHI TANABE PHARMA CORP·Filed 2025·Application pending·0 cites
- 2366US11905308B2Nucleic acid compound and oligonucleotideUNIV OSAKA·Filed 2022·Granted Feb 20, 2024·0 cites·18 claims
- 2463US12104154B2Antisense oligonucleic acidUNIV OSAKA·Filed 2022·Granted Oct 1, 2024·0 cites·16 claims
- 2562US2025179109A15'-modified nucleoside and nucleotide using sameUNIV OSAKA·Filed 2023·Application pending·0 cites
- 2662US2024409919A1Method for separating components using supercritical fluid chromatographSHIMADZU CORP·Filed 2024·Application pending·0 cites
- 2762US2024240183A1Heteronucleic acid containing scpBNA or AmNAUNIV NAT CORP TOKYO MEDICAL & DENTAL·Filed 2022·Application pending·0 cites
- 2859US2025136613A1Phenoxazine derivative and drug delivery system formulation using sameUNIV OSAKA·Filed 2022·Application pending·0 cites
- 2957US12338265B2Crosslinked artificial nucleic acid ALNAMITSUBISHI TANABE PHARMA CORP·Filed 2019·Granted Jun 24, 2025·0 cites·36 claims
- 3054US2024240176A1Prevention or treatment of myopathy using mir-33b inhibitorUNIV KYOTO·Filed 2022·Application pending·0 cites
- 3151US2022177509A1Production of bridged artificial nucleosidesNIPPON CATALYTIC CHEM IND·Filed 2020·Application pending·0 cites
- 3250US12071624B2Antisense oligonucleotide targeting ARL4C molecule, and nucleic acid drug using antisense oligonucleotideUNIV OSAKA·Filed 2019·Granted Aug 27, 2024·0 cites·13 claims
- 3350US2024148775A1Oligonucleotide for inducing n-exon skipping during rest mrna precursor processingUNIV OSAKA·Filed 2022·Application pending·0 cites
- 3449US12473299B2Cross-linked nucleoside and nucleotide using sameUNIV OSAKA·Filed 2021·Granted Nov 18, 2025·0 cites·19 claims
- 3549US2023159924A1Prevention or treatment of aneurysms using mir-33b inhibitorMITSUBISHI TANABE PHARMA CORP·Filed 2021·Application pending·0 cites
- 3648US11866705B2Small cell lung cancer therapeutic agent containing oligonucleotideUNIV OSAKA·Filed 2019·Granted Jan 9, 2024·0 cites·4 claims
- 3748US2022282248A1Molecular targeted nucleic acid medicine for gastric cancerNATIONAL UNIV CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM·Filed 2020·Application pending·0 cites
- 3847US8680260B218F-labeled azide compound, reagent for 18F-labeling and method for 18F-labeling of alkyne compound using sameWATANABE YASUYOSHI·Filed 2010·Granted Mar 25, 2014·0 cites·6 claims
- 3947US2022127300A15'-modified nucleoside and nucleotide using sameUNIV OSAKA·Filed 2020·Application pending·0 cites
- 4047US2005176941A1Nucleoside analogues whose sugar moieties are bound in s-form and oligonucleotide derivatives comprising nucleotide analogues thereofFiled 2003·Application pending·0 cites
- 4145US12398171B25′-modified nucleoside and nucleotide using sameUNIV OSAKA·Filed 2020·Granted Aug 26, 2025·0 cites·17 claims
- 4245US11479773B2Antisense nucleic acid for inhibiting biosynthesis of chondroitin sulfateAICHI MEDICAL UNIV·Filed 2018·Granted Oct 25, 2022·0 cites·15 claims
- 4344US2023113556A1Antisense nucleic acid targeting apoc3NAT CEREBRAL & CARDIOVASCULAR CT·Filed 2021·Application pending·0 cites
- 4443US2015337002A1Nucleoside and nucleotide having sulfonamide structureUNIV OSAKA·Filed 2014·Application pending·0 cites
- 4542US2020172903A1ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSIONUNIV OSAKA·Filed 2018·Application pending·0 cites
- 4642US2014323709A1Oligonucleotide and therapeutic agent for hyperlipidemia containing same as active ingredientNAT CEREBRAL & CARDIOVASCULAR CT·Filed 2012·Application pending·0 cites
- 4741US10190117B2Double-stranded antisense nucleic acid with exon-skipping effectUNIV NAT CORP TOKYO MEDICAL & DENTAL·Filed 2014·Granted Jan 29, 2019·0 cites·14 claims
- 4841US2005059617A1Novel anitsense oligonucleotide derivatives against to hepatitis c virusTAKESHI IMANISHI·Filed 2002·Application pending·0 cites
- 4939US2017211073A1Antisense antineoplastic agentNAKANO KENJI·Filed 2015·Application pending·0 cites
- 5035US11234995B2α-synuclein expression inhibitorUNIV OSAKA·Filed 2017·Granted Feb 1, 2022·0 cites·13 claims
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Satoshi Obika files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →